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Summary  Staphylococcus  aureus  is  the  pathogen  most  frequently  implicated  in  infection  on
orthopedic  hardware;  various  strategies  are  deployed  to  limit  the  risk  of  transmission  and
surgical infection.
Objectives:  The  present  study  is  based  on  a  meta-analysis  assessing  ﬁrstly  the  relationship
between nasal  carriage  of  S.  aureus  and  the  development  of  osteo-articular  infection  and
secondly current  methods  of  decolonization.
Results:  The  meta-analysis  showed  increased  risk  of  surgical  site  infection  in  case  of  nasal
carriage  of  S.  aureus:  OR  =  5.92,  95%  CI  [1.15—30.39];  P  =  0.033.  For  cross-transmission,  a  scien-
tiﬁcally proven  reduction  in  surgical  site  S.  aureus  levels  is  ensured  by  associated  mupirocin  and
2% chlorhexidine  antiseptic  solution  in  subjects  with  positive  nasal  screening  results  for  all  sur-
gical procedures  taken  together;  the  reduction  was  not,  however,  signiﬁcant  in  the  orthopedic
surgery  subgroup.  The  meta-analysis  conﬁrmed  these  ﬁndings:  OR  =  0.60,  95%  CI  [0.34—1.06];
P =  0.08.
Conclusion:  The  literature  review  conﬁrmed  that  nasal  carriage  of  S.  aureus  is  a  major  risk
factor for  surgical  site  infection.  The  efﬁcacy  of  eradication  could  not  be  demonstrated  for
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orthopedic  surgery  as  samples  were  too  small.  The  positive  trend  found,  however,  should
encourage further  studies  with  sufﬁcient  power  and  risk/beneﬁt  should  meanwhile  be  assessed
on a  case-by-case  basis.
Level  of  evidence:  Level  2.  Meta-analysis.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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nfection  on  material  is  one  of  the  most  frequent
omplications  in  orthopedic  surgery.  The  number  of  orthope-
ic  implantation  procedures  in  France  in  2009  was  estimated
y  the  PMSI  information  system  at  229,171,  with  125,340
ip  replacements,  71,122  knee  replacements,  9320  shoulder
eplacements  and  23,389  revision  procedures.  Systematic
erioperative  antibioprophylaxis  and  theater  air  ﬁltration
y  laminar  ﬂow  or  ceiling  ventilation  would  seem  to  have
educed  peroperative  infection  rates.  The  most  recent  ISO-
AISIN  survey  of  838  health  establishments  in  2008  reported
.26%  incidence  of  surgical  site  infection  (SSI)  [1].  A  ret-
ospective  study  of  femoral  neck  fractures  conducted  by
n  antibioprophylaxis  research  group  for  the  ﬁrst  quarter
f  2005  reported  an  SSI  rate  of  5.6%  at  1  year’s  follow-up
2];  Staphylococcus  aureus  was  the  most  frequent  pathogen
37%)  implicated  in  post-surgical  infections.  Traditionally,
revention  of  S.  aureus  infection  is  founded  on  controlling
ross-transmission:  i.e.,  from  patient  to  patient  and  envi-
onment  to  patient  (usually  via  the  care-team’s  hands);  this
an  be  called  ‘‘hand-carriage  prevention’’.
The  literature  reports  three  strategies  of  S.  aureus  SSI
revention:  screening  for  and  isolating  methicillin-resistant
.  aureus  (MRSA)  carriers;  vancomycin  antibioprophylaxis  in
atients  at  risk  of  MRSA;  and  local  decontamination  [3].
owever,  80%  of  nosocomial  S.  aureus  infections  come  from
he  patient’s  own  ﬂora  [4].  Longitudinal  studies  reported
hat  about  20%  of  the  population  are  permanent  and  30%
ntermittent  S.  aureus  carriers  [5].  There  are  several  types
f  colonization  site,  usually  associated  but  sometimes  iso-
ated.  Isolated  nasal  carriage  is  estimated  at  15.6%,  isolated
haryngeal  carriage  at12.4%  and  the  association  at  20.8%
6].  Nasal  carriage  is  a  frequently  reported  risk  factor
7—12]  and  many  studies  have  demonstrated  the  efﬁcacy
f  mupirocin  in  carriage  eradication  [13—21].
However,  two  questions  remain:  is  there  a  correlation
etween  nasal  S.  aureus  carriage  and  osteo-articular  infec-
ion;  and  what  methods  of  decolonization  exist  and  with
hat  efﬁcacy?
ethod
o  address  these  questions,  a  literature  review  was  con-
ucted  with  the  inclusion  criteria  and  strategy  outlined
elow.nclusion  criteria
sing  the  French  Health  Authority  (HAS)  levels  of  evi-
ence  (ANAES  2000  guidelines  for  literature  analysis  and
S
R
Cecommendations  grading),  prospective  randomized  studies
level  of  evidence  1)  were  selected  in  priority,  and  supple-
ented  by  cohort  studies,  well-conducted  non-randomized
omparative  studies  or  low-power  randomized  comparative
tudies  (level  of  evidence  2),  case-control  studies  (level  of
vidence  3)  and  retrospective  studies,  comparative  stud-
es  with  signiﬁcant  bias  or  case  series  (level  of  evidence
),  assessing  prevention  of  S.  aureus  infection  following
rthopedic  surgery  in  nasal  S.  aureus  carriers,  regardless
f  gender  and  age.  Recommendation  grades  were  classiﬁed
ccording  to  the  above  guidelines  as:  grade  A,  established
cientiﬁc  proof  (level  of  evidence  1);  grade  B,  presumptive
cientiﬁc  demonstration  (level  of  evidence  2);  grade  C,  low
evel  of  evidence  (levels  of  evidence  3  or  4).
Studies  in  which  nasal  carriage  was  detected  either  by
ell  culture  or  by  genomic  ampliﬁcation  were  candidates
or  inclusion.
Results  were  required  to  distinguish  carriers  and  non-
arriers  of  S.  aureus.  When  preventive  treatment  was
dministered  before  surgery,  the  control  group  could  either
eceive  placebo  or  no  treatment.
The  principle  assessment  criterion  was  percentage
ethicillin  susceptible  or  resistant  SSI,  according  to  the  Cen-
ers  for  Disease  Control  and  Prevention  (CDC)  criteria  [7].
earch  strategy
he  search  of  the  literature  applied  key-words  to  the
ochrane  Central  Register  of  Controlled  Trials  (latest  ver-
ion),  EMBASE  and  MEDLINE  (up  to  January  2011).
To  seek  answers  to  the  questions  of  the  relationship
etween  nasal  carriage  and  risk  of  postoperative  S.  aureus
steo-articular  infection  and  of  the  various  decolonization
ethods  and  their  relative  efﬁcacy,  the  following  key-words
ere  entered,  alone  or  combined:
 ‘‘nasal  carriage  S.  aureus’’;
 and  ‘‘orthopedic  or  bone  surgery’’;
 and  ‘‘nasal  carriage  S.  aureus  and  mupirocin’’;
 or  ‘‘S.  aureus  and  surgical  site  infection  and  mupirocin’’;
 or  ‘‘S.  aureus  and  surgical  site  infection  and  chlorhexi-
dine’’;
 or  ‘‘nasal  carriage  S.  aureus  and  decontamination’’.
Selection  was  duplicated  (PYL,  MD)  and  discordances
ere  discussed.tatistical  analysis
esults  were  presented  using  the  forest  plot  option  of  the
omprehensive  Meta-analysis  package  (Biostat).  Percentage
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Figure  2  Effect  of  nasal  Staphylococcus  aureus  carriage  on
surgical  site  infection.  Point  forest  display.  The  last  line  cor-
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aFigure  1  Effect  of  nasal  carriage:  selection  procedure  for
studies meeting  the  inclusion  criteria.
S.  aureus  infection  was  expressed  as  relative  risk  (RR)  with
95%  conﬁdence  intervals.  Results  from  different  studies
were  compiled  on  the  random  effects  model,  as  they  were
not  based  on  the  same  methodology.  Heterogeneity  was
analyzed  on  Chi2,  with  a  signiﬁcance  threshold  of  P =  0.05.
I2 >  50%  indicated  signiﬁcant  heterogeneity  between  studies.
Results
Is  there  a  relationship  between  nasal  S.  aureus
carriage  and  the  development  of  osteo-articular
infection?
An  initial  search  using  ‘‘nasal  carriage  S.  aureus’’  retrieved
860  references,  reduced  to  25  by  crossing  with  ‘‘orthopedic
or  bone  surgery’’  (Fig.  1).  A  total  of  ﬁve  studies  in  orthope-
dic  surgery  were  selected;  the  other  20  were  excluded  either
because  they  did  not  concern  joint  surgery  or  because  they
failed  to  provide  carrier  data:
•  Kalmeijer  et  al.  [8]  (Level  of  evidence:  2)  demonstrated
in  2000  that  the  sole  independent  risk  factor  for  postop-
erative  S.  aureus  infection  was  signiﬁcant  nasal  S.  aureus
carriage  (P  =  0.002).  Semi-quantitative  screening  was
performed  in  a  cohort  of  272  patients  admitted  for
implantation:  27%  screened  positive  (10%  weakly);  18/272
(6.6%)  developed  SSI,  including  nine  implicating  S.  aureus,
six  of  whom  had  screened  positive;
•  Hacek  et  al.  [9]  (Level  of  evidence:  3)  assessed  a  detection
and  decolonization  program  in  a  non-randomized  study  of
912  patients  and  583  controls.  223  of  the  912  patients  fol-
lowed  up  at  2—4  weeks  postoperatively  screened  positive
and  received  mupirocin  twice  daily  for  5  days  up  to  the
eve  or  morning  of  surgery:  three  developed  SSI;  four  of
the  689  negative  patients  developed  infection.  Ten  of  the
583  control  subjects  (416  from  a  historic  group  and  167
concomitantly  admitted  but  not  involved  in  the  program)
developed  infection.  The  screening  and  decolonization
program  obtained  a  signiﬁcant  reduction  in  SSI  at  1  year
in  patients  who  screened  positive  and  underwent  decol-
onization  (P  <  0.05;  95%  CI  =  2.2—10);  in  the  192  patients
taken  as  a  whole,  carriers  and  non-carriers,  there  was  no
signiﬁcant  reduction  (P  <  0.1%);
•  Price  et  al.  [10]  (Level  of  evidence:  2)  analyzed  pre-
operative  nasal  carriage  in  orthopedic  surgery.  Eighty-six
out  of  284  patients  were  S.  aureus  carriers,  including  ﬁve
r
•esponds  to  the  summary  effect  on  the  random  effects  model:
R =  5.92,  95%  CI  [1.15—30.39];  P  =  0.03.
with  MRSA.  Four  of  the  284  developed  SSI:  zero  of  the  43
decolonized  by  mupirocin,  two  carriers  who  had  refused
decolonization,  and  two  of  the  196  non-carriers.  Sample
sizes  were  too  small  to  demonstrate  signiﬁcance;
 Yano  et  al.  [11]  (Level  of  evidence:  2)  studied  the  relation
between  pre-existent  nasal  MRSA  carriage  and  MRSA  ISS
in  a  cohort  of  2423  orthopedic  in-patients  followed  up
for  26  months:  incidence  differed  between  carriers  and
non-carriers  (4/63  vs.  11/2,360,  respectively;  P  = 0.001);
 Berthelot  et  al.  [12]  (Level  of  evidence:  2)  performed
a  multicenter  study,  including  3908  patients.  S.  aureus
was  detected  pre-operatively  in  790  (20%)  patients.  There
were  77  cases  of  SSI,  22  of  which  implicated  S.  aureus.
Nine  of  the  77  cases  were  carriers,  although  only  in  six
was  the  strain  the  one  that  was  detected  preoperatively.
The  study  involved  a methodological  limitation,  as  in  half
of  the  nine  cases  (5/9),  strains  were  compared  by  pheno-
typic  analysis  of  an  antibiogram  based  on  a  single  clone,
whereas  carriage  may  be  multiclonal.
The  present  meta-analysis  of  these  ﬁve  studies  focus-
ng  on  osteo-articular  infection  (Fig.  2)  found  a  signiﬁcant
mpact  of  nasal  S.  aureus  on  S.  aureus  SSI:  OR  =  5.92,  95%
I  [1.15—30.39];  P  =  0.033.  The  random  effects  model  was
sed,  as  heterogeneity  was  elevated:  I2 =  90;  P  <  0.001.
hat  methods  of  decolonization  are  used,  with
hat efﬁcacy?
he  initial  search  for  ‘‘nasal  carriage  S.  aureus’’ retrieved
60  references,  reduced  to  185  when  crossed  with
‘mupirocin’’,  to  25  when  crossed  with  ‘‘orthopedic  or  bone
urgery’’  and  to  seven  with  all  three  key-words  (Fig.  3).
ix  studies  dedicated  to  orthopedic  surgery  were  analyzed
ogether;  a  study  of  nasal  decontamination  associated  to
ntiseptic  douche  was  analyzed  separately.
solated  nasal  decontamination
e  shall  ﬁrst  present  three  systematic  reviews  of  the  liter-
ture  [13—15]  and  one  meta-analysis  [16], which  recently
eported  on  mupirocin  in  postoperative  S.  aureus  infection:
 Kallen  et  al.  [13],  analyzing  three  randomized  trials  and
four  cohort  studies,  found  no  reduction  in  SSI  in  general
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cigure  3  Nasal  decolonization.  Selection  procedure  for  stud-
es meeting  the  inclusion  criteria.
surgery,  but  a  signiﬁcant  effect  of  mupirocin  in  spe-
cialized  (cardiothoracic  and  orthopedic)  surgery  in  the
randomized  studies.  Only  one  randomized  study  [17]  and
one  cohort  study  [18]  speciﬁcally  focused  on  orthopedic
surgery;
 Trautman  et  al.  [14],  analyzing  four  randomized  trials
and  seven  cohort  studies  of  nasal  decontamination  ver-
sus  placebo  or  no  treatment  in  SSI  prophylaxis  in  elective
surgery,  found  no  reduction  in  S.  aureus  SSI  with  mupirocin
in  orthopedic,  digestive  or  cardiac  surgery.  Only  one
randomized  study  [17]  and  two  cohort  studies  [18,19]
speciﬁcally  focused  on  orthopedic  surgery;
 These  reviews  mixed  together  results  for  systematic
treatment  of  all  patients  and  targeted  treatment.  In  con-
trast,  Van  Rijen  et  al.  [15]  (Level  of  evidence:  1)  analyzed
mupirocin  efﬁcacy  speciﬁcally  in  patients  screening  pos-
itive  for  nasal  S.  aureus. There  were  four  randomized
trials,  including  1  in  orthopedic  surgery  [17].  Treatment
duration,  however,  varied  from  1  to  7  days,  depending
on  the  study.  Mupirocin  reduced  the  rate  of  nosoco-
mial  S.  aureus  infection  as  a  whole  (RR  =  0.55,  95%  CI
[0.34—0.89]),  but  there  was  no  signiﬁcant  difference  for
SSI  in  particular.  The  authors  attributed  this  to  lack  of
power:  expected  SSI  rates  in  the  placebo  group  greater
than  those  observed,  multifactor  causes  of  SSI  onset,  and
heterogeneous  surgery  population;
 The  Cochrane  Collaboration  publishes  a  systematic  review
of  mupirocin  efﬁcacy  in  the  prevention  of  S.  aureus  infec-
tion.  A  meta-analysis  by  Van  Rijen  published  in  2008  [16]
(Level  of  evidence:  1)  showed  that,  in  nasal  S.  aureus  car-
riers,  mupirocin  signiﬁcantly  reduced  S.  aureus  infection
(RR  =  0.55,  95%  CI  [0.43—0.70]).  There  were  nine  random-
ized  controlled  trials,  four  of  which  concerned  surgery
patients  (but  only  one  for  orthopedic  surgery  [17]).  The
surgery  sub-group  showed  a  signiﬁcant  reduction  in  noso-
comial  S.  aureus  infection  with  mupirocin  (RR  =  0.56,  95%
CI  [0.34—0.91]),  but  which  failed  to  extend  to  SSI  speciﬁ-
cally  (RR  =  0.63,  95%  CI  [0.38—1.04]).  The  authors  explain
that  this  particular  analysis  was  not  planned  for  in  the
study  design,  whence  a  lack  of  power.
Of  the  six  studies  considered  for  the  present  meta-
nalysis,  only  one  DBRPCT  (double-blind  randomized
c
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lacebo  controlled  trial)  [17]  and  an  orthopedic  surgery
ubgroup  within  a  randomized  double-blind  trial,  but  asso-
iating  mupirocin  to  chlorhexidine  [20],  met  the  selection
riteria.  Kalmeijer  et  al.’s  DBRPCT  [17]  (Level  of  evidence:
)  included  614  patients  scheduled  for  orthopedic  implant
urgery.  Mupirocin  and  placebo  were  administered  twice
aily  to  315  and  299  patients  respectively  at  eve  and  morn-
ng  of  surgery.  Possible  SSI  was  investigated  for  1  month’s
ollow-up.  Baseline  colonization  was  30%  in  the  mupirocin
roup  and  29%  in  the  placebo  group;  16%  of  positive  samples
15/95)  remained  positive  at  3  to  5  days  in  the  mupirocin
roup,  versus  71%  (61/86)  in  the  placebo  group,  demonstrat-
ng  efﬁcacy.  However,  no  signiﬁcant  impact  could  be  shown
n  SSI  due  to  lack  of  power:  there  was  a  trend  toward  efﬁ-
acy  (12/315  [4%]  vs.  14/299  [5%]),  but  the  difference  was
ot  signiﬁcant  as  the  infection  rate  in  the  placebo  group  was
ower  than  expected  although  higher  than  in  the  literature
n  general.
Two  open  but  non-randomized  studies  in  orthopedic
urgery  included  S.  aureus  carriers  and  non-carriers,  with
istoric  control  groups:
 Gernaat  van  der  Sluis  et  al.  [18]  (Level  of  evidence:
2),  comparing  1044  patients  treated  with  mupirocin  and
1,260  controls  without  treatment,  found  a  signiﬁcant
reduction  in  SSI  (P  =  0.02);
 Wilcox  [19]  (Level  of  evidence:  4),  did  not  report  percent-
ages,  but  claimed  that  SSI  was  unaffected  by  mupirocin;
this  study  was  excluded  from  analysis.
Since  2008,  three  non-randomized  cohort  studies  of
upirocin  have  focused  exclusively  on  orthopedic  surgery.
 Rao  et  al.  [20]  (Level  of  evidence:  2),  in  a  non-randomized
study,  compared  636  arthroplasty  patients  with  screening
and  decolonization  when  positive  and  two  control  groups:
one  operated  on  1  year  before  the  study  and  the  other
without  decolonization.  In  the  study  group,  164/636  (26%)
screened  positive  and  none  showed  SSI  over  1  year’s
follow-up;  12  (3.5%;  P  =  0.016)  of  an  estimated  346  car-
riers  in  a  control  population  of  1330  (26%)  had  S.  aureus
infection;
 Hacek  et  al.  [9]  (Level  of  evidence:  3),  in  a  non-
randomized  study,  reported  that  a screening  and
decolonization  program  signiﬁcantly  reduced  SSI  in  decol-
onized  (i.e.,  S.  aureus  positive)  patients  (P  <  0.05;  95%
[2.2—10]);
 Savor  Price  et  al.  [10]  (Level  of  evidence:  2)  analyzed
preoperative  nasal  carriage  in  284  orthopedic  surgery
patients  but,  as  previously  noted,  with  insufﬁcient  power
to  demonstrate  any  difference.
asal  decolonization  associated  to  antiseptic  douche
he  efﬁcacy  of  whole-body  chlorhexidine  4%  douche  against
RSA  strains  was  reported  in  a  double-blind  randomized
rial  [21]  (Level  of  evidence:  1).  Intranasal  mupirocin  asso-
iated  to  chlorhexidine  soap  proved  effective  against  MRSA
arriage  in  patients  under  hemodialysis  [22].  Efﬁcacy  was
ikewise  demonstrated  in  SSI  in  a  randomized  study  of  carrier
urgery  patients.  Bode  et  al.  [23]  (Level  of  evidence:  1)  per-
ormed  a  randomized  double-blind  study  of  6771  patients,
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Figure  4  Effect  of  mupirocine  on  Staphylococcus  aureus  surgical  site  infection.  Point  forest  display.  Mupirocin:  group  receiving
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mpre-operative mupirocin.  Control:  no  preventive  treatment.  The
model: OR  =  0.60,  95%  CI  [0.34—1.06];  P  =  0.08.
1251  of  whom  screened  positive  (18.8%).  913  were  random-
ized:  505  with  two  local  applications  of  mupirocin  daily  for
5  days  and  daily  chlorhexidine  antiseptic  douche,  versus  413
placebos.  S.  aureus  infection  was  signiﬁcantly  lower  in  the
treatment  group  (RR  =  0.42,  95%  CI  [0.23—0.75]),  and  more
especially  in  deep  SSI  (RR  =  0.21,  95%  CI  [0.07—0.62]).  The
SSI  ratio,  however,  was  not  reported.  For  the  172  ortho-
pedic  surgery  patients,  there  was  no  signiﬁcant  difference
between  treatment  and  placebo  groups  (RR  =  0.25,  95%  CI
[0.03—2.26]).
A  meta-analysis  of  six  studies  (with  full  or  partial
study  data)  focusing  speciﬁcally  on  osteo-articular  infection
(Fig.  4)  found  a  trend  for  mupirocin  to  reduce  S.  aureus  SSI:
OR  =  0.60,  95%  CI  [0.34—1.06];  P  =  0.08.
Choice  of  molecule
Mupirocin  is  the  most  frequently  studied  molecule  for  the
eradication  of  nasal  S.  aureus  carriage  and  its  efﬁcacy  has
been  convincingly  demonstrated  in  randomized  double-blind
trials  [21—23]  (All  level  of  evidence  1).  Another  random-
ized  double-blind  trial  showed  it  to  be  more  effective
than  bacitracin  [24]  (Level  of  evidence:  1),  and  it  proved
more  effective  than  Neomycin  sulfate  in  a  lower  level
study  [25]  (Level  of  evidence:  3).  Comparable  results  were
found  in  an  open  trial  against  an  association  of  topical
fusidic  acid  and  oral  trimethoprim—sulfamethoxazole  [26]
(Level  of  evidence:  2).  A  recent  randomized  double-blind
trial  comparing  Polysporin  Triple  (PT:  polymixin  B,  baci-
tracin,  gramicidin)  versus  mupirocin  found  PT  to  be  less
effective  at  12  weeks  in  eradicating  MRSA  [27]  (Level  of
evidence:  1).  Batumin  ointment  was  studied  in  56  health-
care  staff  in  Ukraine  [28]  (Level  of  evidence:  3),  and
found  to  be  more  effective  than  mupirocin  or  associ-
ated  bacitracin-Neomycin;  this  was,  however,  an  isolated
study.
The  choice  of  antiseptic  is  important:  a  randomized
double-blind  trial  found  2%  alcoholic  chlorhexidine  to  be
signiﬁcantly  more  effective  than  iodized  povidone  in  pre-
venting  superﬁcial  (P  =  0.008)  and  deep  (fascia,  muscles:
P  =  0.05)  SSI  [29]  (Level  of  evidence:  1).  Likewise,  a  recent
meta-analysis  of  blood-culture  contamination  prevention
showed  alcoholic  chlorhexidine  to  be  more  effective  than
aqueous  iodized  povidone  (RR:  0.33,  95%  CI  [0.24—0.46])
f
p
t line  corresponds  to  the  summary  effect  on  the  random  effects
30]; however,  chlorhexidine  concentration  varies  with  the
xcipient  (4%  soap,  2%  alcohol).
iscussion
he  literature  review  was  intended  to  address  two  ques-
ions:  is  there  a  relation  between  nasal  S.  aureus  carriage
nd  onset  of  osteo-articular  infection?  And  what  decolo-
ization  methods  exist  and  what  is  their  efﬁcacy,  notably  as
egards  the  association  of  local  mupirocin  and  chlorhexidine
or  other  disinfectant)  douche?
Nasal  carriage  is  a  well-established  risk  factor  for
nfection  in  patients  undergoing  surgery  or  dialysis,  intravas-
ular  device  bearers,  liver  cirrhosis  patients  and  those
n  intensive  care  [31].  A  very  recent  genetic  association
tudy  using  multilocus  sequence  typing  and  identiﬁcation
f  hypervariable  gene  regions  coding  for  clumping  fac-
or  and  ﬁbronectin  demonstrated  a  strong  relationship
etween  asymptomatic  nasal  carriage  strains  and  those
ound  in  clinical  samples  [32].  Munoz  et  al.  [33]  deter-
ined  independent  risk  factors  for  infection  after  cardiac
urgery:  multivariate  analysis  identiﬁed  nasal  S.  aureus  car-
iage  (RR  =  3.1),  re-do  surgery  and  diabetes.  The  present
eta-analysis,  based  on  a  single  randomized  study  and
ome  non-randomized  studies  in  orthopedic  surgery  con-
rmed  this  risk;  the  levels  of  evidence  allow  a  strong
cientiﬁc  presumption  of  correlation  between  S.  aureus
arriage  and  S.  aureus  SSI  (grade  B  recommendation).
any  reports  conﬁrm  the  high  efﬁcacy  of  mupirocin  ver-
us  placebo  in  eradication  of  nasal  S.  aureus  carriage
ver  the  short  term,  which  is  quite  long  enough  for
he  purposes  of  SSI  prevention  [13—21];  where  long-
erm  treatment  is  indicated,  however,  mupirocin  fails  to
nsure  eradication  and  the  risk  of  developing  resistance  is
ncreased.
The  efﬁcacy  of  mupirocin  in  infection  prevention  by  car-
iage  eradication  has  been  clearly  demonstrated,  with  a
igniﬁcant  reduction  in  S.  aureus  infection  in  general.  The
eta-analysis,  however,  failed  to  demonstrate  reductionor  SSI  in  particular,  probably  due  to  lack  of  statistical
ower.
In  all,  the  levels  of  evidence  of  the  above  studies  support
he  following  conclusions:
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 there  is  established  scientiﬁc  evidence  (grade  A  recom-
mendation)  that  mupirocin  is  more  effective  than  other
agents  in  eradicating  nasal  S.  aureus  carriage  [23—34];
 there  is  established  scientiﬁc  evidence  (grade  A  rec-
ommendation)  that  2%  alcoholic  chlorhexidine  is  more
effective  than  aqueous  iodized  povidone  in  preventing
superﬁcial  and  deep  infection  [21,22];
 there  is  no  established  scientiﬁc  evidence  that  mupirocin
alone  reduces  the  risk  of  orthopedic  S.  aureus  SSI  [17,18]:
the  cited  studies  report  a  sub-signiﬁcant  trend;
 there  is,  on  the  other  hand,  established  scientiﬁc
evidence  (grade  A  recommendation)  for  a  signiﬁcant
reduction  in  S.  aureus  SSI  with  associated  mupirocin  and
2%  chlorhexidine  antiseptic  solution  in  case  of  positive
nasal  screening,  but  this  signiﬁcant  reduction  fails  to  hold
for  the  orthopedic  surgery  subgroup  [23].
The  present  meta-analysis  of  the  above  studies  con-
rmed  this  sub-signiﬁcant  trend  toward  efﬁcacy.  Several
xplanations  may  be  given  for  the  failure  to  demonstrate
igniﬁcance.  Firstly,  a  very  high  number  of  patients  is
tatistically  required  in  each  arm,  as  the  prevalence  of  post-
perative  infection  in  orthopedic  surgery  is  less  than  1%.
econdly,  non-nasal,  and  notably  pharyngeal,  infection  sites
6,35]  also  cause  contamination,  but  decontaminating  them
s  more  difﬁcult  and  seldom  attempted.  Nasal  carriage  by
taff  is  known  to  be  an  external  source  of  contamination
36,37]  and  may  also  be  a  source  of  bias:  recent  studies  have
hown  that  staff  decontamination  by  mupirocin  reduced  the
ate  of  patient  infection  in  orthopedic  surgery  [38].  It  may
lso  sometimes  be  difﬁcult  to  implement  patient  decon-
amination  protocols,  given  the  diagnosis  time  (2  days  per
ulture)  and  treatment  duration  (3  days,  but  varying  up  to
 days  according  to  the  study):  decontamination  may  thus
e  too  late  or  impossible  with  respect  to  surgery,  especially
n  traumatology  or  emergency  settings.  Finally,  failure  to
istinguish  carriers  and  non-carriers  will  have  reduced  the
bserved  efﬁcacy  of  mupirocin  in  certain  of  the  studies.
onclusion
asal  carriage  is  a  major  risk  factor  for  orthopedic  surgical
ite  infection.  Given  the  proven  efﬁcacy  of  associating  local
upirocine  for  5  days  before  surgery  to  2%  chlorhexidine
ouche  in  preventing  S.  aureus  infection  (grade  A  recom-
endation),  even  though  this  was  reduced  to  a  mere  trend
n  the  results  restricted  to  orthopedic  surgery  because  of  a
hortage  of  randomized  studies,  the  beneﬁt  of  this  associ-
tion  on  patients  who  screen  positive  should  be  considered
n  a  case  by  case  basis.  In  surgery  that  is  urgent  or  sched-
led  within  6  days,  systematic  mupirocin  with  no  screening
r  relying  on  rapid  molecular  biology  tests  is  worth  investi-
ating.
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